Journal of pediatric gastroenterology and nutrition · 2026
Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic-associated diarrhoea in children.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Szajewska Hania, Kołodziej Maciej, Zalewski Bartłomiej M, Dinleyici Ener Cagri, Łukasik Jan
Аннотация
OBJECTIVES: Probiotic effects are strain-specific; each strain needs to be assessed individually. In this review, we evaluated the effectiveness of Limosilactobacillus reuteri DSM 17938 in preventing antibiotic-associated diarrhoea (AAD) in children receiving systemic antibiotics.
METHODS: We searched the Cochrane Library, MEDLINE, EMBASE and trial registries (January 2016-July 2025) for randomized controlled trials (RCTs) comparing L. reuteri DSM 17938 with placebo, no treatment, or other probiotics in children. Risk of bias was assessed with Risk of Bias 2 (ROB-2), and certainty of evidence with Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
RESULTS: Three RCTs (1070 randomized, 998 analysed) were included. No significant effect was observed with ≤14-day administration (two RCTs, n = 901; risk ratio [RR] 0.85, 95% confidence interval [CI]: 0.26-2.77; low certainty evidence), with interpretation limited by heterogeneity (I2 = 91%) and analytical differences. A regimen of up to 21 days reduced AAD risk (two RCTs, n = 751; RR: 0.50, 95% CI: 0.33-0.75; moderate certainty evidence). A post hoc analysis of trials with follow-up up to 56 days showed no significant effect (three RCTs, n = 998; RR: 0.85, 95% CI: 0.29-2.46; I2 = 83%). A subgroup analysis limited to children receiving amoxicillin-clavulanate showed benefit (two RCTs, n = 690; RR: 0.49, 95% CI: 0.32-0.76; I2 = 0%).
CONCLUSIONS: L. reuteri DSM 17938 may reduce the risk of AAD in children when administered for up to 21 days or in those receiving amoxicillin-clavulanate. No benefit was found with shorter administration or extended follow-up. Further high-quality trials are needed before routine use can be recommended.
METHODS: We searched the Cochrane Library, MEDLINE, EMBASE and trial registries (January 2016-July 2025) for randomized controlled trials (RCTs) comparing L. reuteri DSM 17938 with placebo, no treatment, or other probiotics in children. Risk of bias was assessed with Risk of Bias 2 (ROB-2), and certainty of evidence with Grading of Recommendations, Assessment, Development and Evaluation (GRADE).
RESULTS: Three RCTs (1070 randomized, 998 analysed) were included. No significant effect was observed with ≤14-day administration (two RCTs, n = 901; risk ratio [RR] 0.85, 95% confidence interval [CI]: 0.26-2.77; low certainty evidence), with interpretation limited by heterogeneity (I2 = 91%) and analytical differences. A regimen of up to 21 days reduced AAD risk (two RCTs, n = 751; RR: 0.50, 95% CI: 0.33-0.75; moderate certainty evidence). A post hoc analysis of trials with follow-up up to 56 days showed no significant effect (three RCTs, n = 998; RR: 0.85, 95% CI: 0.29-2.46; I2 = 83%). A subgroup analysis limited to children receiving amoxicillin-clavulanate showed benefit (two RCTs, n = 690; RR: 0.49, 95% CI: 0.32-0.76; I2 = 0%).
CONCLUSIONS: L. reuteri DSM 17938 may reduce the risk of AAD in children when administered for up to 21 days or in those receiving amoxicillin-clavulanate. No benefit was found with shorter administration or extended follow-up. Further high-quality trials are needed before routine use can be recommended.